Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply
- PMID: 31875508
- DOI: 10.1056/NEJMc1915739
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply
Comment on
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.N Engl J Med. 2020 Jan 2;382(1):92. doi: 10.1056/NEJMc1915739. N Engl J Med. 2020. PMID: 31875506 No abstract available.
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.N Engl J Med. 2020 Jan 2;382(1):92-93. doi: 10.1056/NEJMc1915739. N Engl J Med. 2020. PMID: 31875507 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical